PharmaMar said FY2025 net profit rose 187% to EUR 75.0 million as total revenue increased 27% to EUR 221.4 million. EBITDA was EUR 68.1 million, compared with EUR 12.0 million in FY2024. Recurring revenues (net sales plus royalties) rose 12% to EUR 143.5 million, while non-recurring revenues increased 66% to EUR 77.9 million. Year-end cash and cash equivalents were EUR 167.8 million and financial debt was EUR 46.6 million. In oncology, FY2025 net sales grew 20% to EUR 79.7 million, including Zepzelca revenue in Europe of EUR 37.5 million (+31.0%), driven by compassionate use program revenue of EUR 26.2 million (+18.0%) and Switzerland sales of EUR 11.3 million (+77.0%). Raw material sales to partners for lurbinectedin and Yondelis rose 37% to EUR 27.5 million, while commercial sales of trabectedin in Europe were EUR 14.7 million. Oncology royalty income increased 4.0% to EUR 63.8 million, with royalties from U.S. partner Jazz Pharmaceuticals for lurbinectedin at EUR 51.6 million. PharmaMar also reported that U.S. Q4 lurbinectedin sales were about USD 90 million (+15.0%) following FDA approval in October for use with atezolizumab in first-line maintenance treatment in extensive-stage small cell lung cancer. Licensing income rose 67% to EUR 77.8 million, including a EUR 42.5 million milestone for FDA full approval of lurbinectedin, a EUR 21.3 million upfront payment for a Japan licensing agreement for lurbinectedin, and EUR 8.6 million tied to a commercial milestone in the U.S. trabectedin licensing agreement. R&D investment was EUR 95.2 million, with oncology R&D at EUR 92.4 million; the company expects Phase III LAGOON trial results in Q3 2026 and said recruitment for the Phase III SaLuDo trial is expected to complete mid-2026 with data expected in H1 2027. The board will propose a dividend of EUR 1.00 per share, up to EUR 18.0 million.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharma Mar SA published the original content used to generate this news brief on February 27, 2026, and is solely responsible for the information contained therein.
Comments